By Devika Patel
Knoxville, Tenn., Sept. 17 - ChemGenex Pharmaceuticals Ltd. said it took in A$12.93 million in a private placement of stock.
The company sold 15,216,153 ordinary shares at A$0.85 apiece.
Existing major shareholders Alta Partners, GBS Venture Partners and Merck Santé bought A$6.5 million of the shares.
Proceeds will be applied to the continued clinical trial program for the company's lead oncology drug candidate, omacetaxine.
ChemGenex is a biopharmaceutical development company based in Geelong, Australia.
| Issuer: | ChemGenex Pharmaceuticals Ltd.
|
| Issue: | Ordinary stock
|
| Amount: | A$12,933,730.05
|
| Shares: | 15,216,153
|
| Price: | A$0.85
|
| Warrants: | No
|
| Investors: | Alta Partners, GBS Venture Partners and Merck Santé (for A$6.5 million)
|
| Settlement date: | Sept. 17
|
| Stock symbol: | Australia: CXS
|
| Stock price: | A$0.795 at close Sept. 17
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
